{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:46Z","timestamp":1792218346976,"version":"4.4.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:p> PURPOSE: To improve the control of hyperuricemia in patients with leukemia or lymphoma, we tested a newly developed uricolytic agent, recombinant urate oxidase (SR29142; Rasburicase; Sanofi-Synthelabo, Inc, Paris, France), which catalyzes the oxidation of uric acid to allantoin, a highly water-soluble metabolite readily excreted by the kidneys. <\/jats:p><jats:p> PATIENTS AND METHODS: We administered Rasburicase intravenously, at 0.15 or 0.20 mg\/kg, for 5 to 7 consecutive days to 131 children, adolescents, and young adults with newly diagnosed leukemia or lymphoma, who either presented with abnormally high plasma uric acid concentrations or had large tumor cell burdens. Blood levels of uric acid, creatinine, phosphorus, and potassium were measured daily. The pharmacokinetics of Rasburicase, the urinary excretion rate of allantoin, and antibodies to Rasburicase were also studied. <\/jats:p><jats:p> RESULTS: At either dosage, the recombinant enzyme produced a rapid and sharp decrease in plasma uric acid concentrations in all patients. The median level decreased by 4 hours after treatment, from 9.7 to 1 mg\/dL (P = .0001), in the 65 patients who presented with hyperuricemia, and from 4.3 to 0.5 mg\/dL (P = .0001) in the remaining 66 patients. Despite cytoreductive chemotherapy, plasma uric acid concentrations remained low throughout the treatment (daily median level, 0.5 mg\/dL). The urinary excretion rate of allantoin increased during Rasburicase treatment, peaking on day 3. Serum phosphorus concentrations did not change significantly during the first 3 days of treatment, decreased significantly by day 4 in patients presenting with hyperuricemia (P = .0003), and fell within the normal range in all patients by 48 hours after treatment. Serum creatinine levels decreased significantly after 1 day of treatment in patients with or without hyperuricemia at diagnosis (P = .0003 and P = .02, respectively) and returned to normal range in all patients by day 6 of treatment. Toxicity was negligible, and none of the patients required dialysis. The mean plasma half-lives of the agent were 16.0 \u00b1 6.3 (SD) hours and 21.1 \u00b1 12.0 hours, respectively, in patients treated at dosages of 0.15 or 0.20 mg\/kg. Seventeen of the 121 assessable patients developed antibodies to the enzyme. <\/jats:p><jats:p> CONCLUSION: Rasburicase is safe and highly effective for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. <\/jats:p>","DOI":"10.1200\/jco.2001.19.3.697","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:12:12Z","timestamp":1487923932000},"page":"697-704","source":"Crossref","is-referenced-by-count":290,"title":["Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia  or Lymphoma"],"prefix":"10.1200","volume":"19","author":[{"given":"Ching-Hon","family":"Pui","sequence":"first","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem H.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Wiley","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald M.","family":"Woods","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Leverger","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Camitta","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hastings","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory H.","family":"Reaman","sequence":"additional","affiliation":[{"name":"From the St Jude Children\u2019s Research Hospital and University of Tennessee, Memphis, TN; Midwest Children\u2019s Cancer Center, Milwaukee, WI; University of North Carolina, Chapel Hill, NC; Children\u2019s Mercy Hospital, Kansas City, MO; H\u00f4pital Armand Trousseau, Paris, France; Children\u2019s Hospital Medical Center of Northern California, Oakland, CA; Texas Children\u2019s Cancer Center\/Baylor College of Medicine, Houston, TX; and Children\u2019s National Medical Center, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-084315","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90130-5"},{"key":"R2-084315","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(68)80209-4"},{"key":"R3-084315","doi-asserted-by":"crossref","unstructured":"Krakoff  IH,   Murphy  ML:   Hyperuricemia in neoplastic disease in children:   Prevention with allopurinol, a xanthine oxidase inhibitor.   Pediatrics 41:  52,1968-56,","DOI":"10.1542\/peds.41.1.52"},{"key":"R4-084315","doi-asserted-by":"publisher","DOI":"10.1007\/BF00860751"},{"key":"R5-084315","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90286-7"},{"key":"R6-084315","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950180405"},{"key":"R7-084315","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196603032740902"},{"key":"R8-084315","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80387-0"},{"key":"R9-084315","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-62-4-639"},{"key":"R10-084315","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196902202800806"},{"key":"R11-084315","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197008132830708"},{"key":"R12-084315","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(72)90124-2"},{"key":"R13-084315","unstructured":"Shohet  I,   Aladjem  M,   Lotan  D,  et al:  Acute renal failure complicating Burkitt\u2019s lymphoma treated with chemotherapy and allopurinol.   Int J Pediatr Nephrol 1:  240,1980-241,"},{"key":"R14-084315","doi-asserted-by":"crossref","unstructured":"Brogard  JM,   Coumaros  D,   Franckhauser  J,  et al:  Enzymatic uricolysis:   A study of the effect of a fungal urate-oxydase.   Rev Eur Etudes Clin Biol 17:  890,1972-895,","DOI":"10.1088\/0031-9155\/17\/6\/097"},{"key":"R15-084315","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(91)90622-I"},{"key":"R16-084315","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80259-X"},{"key":"R17-084315","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400850"},{"key":"R18-084315","doi-asserted-by":"crossref","unstructured":"Mahmoud  HH,   Leverger  G,   Patte  C,  et al:  Advances in the management of malignancy-associated hyperuricemia.   Br J Cancer 77:  18,1998-20,     (suppl 4)","DOI":"10.1038\/bjc.1998.432"},{"key":"R20-084315","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(98)00200-3"},{"key":"R21-084315","doi-asserted-by":"publisher","DOI":"10.1021\/js960009s"},{"key":"R22-084315","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198105000-00005"},{"key":"R23-084315","doi-asserted-by":"crossref","unstructured":"Stapleton  FB,   Strother  DR,   Roy  S III,  et al:  Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma.   Pediatrics 82:  863,1988-869,","DOI":"10.1542\/peds.82.6.863"},{"key":"R24-084315","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"R25-084315","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2001.19.3.697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:48:20Z","timestamp":1653515300000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2001.19.3.697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,2,1]]}},"alternative-id":["10.1200\/JCO.2001.19.3.697"],"URL":"https:\/\/doi.org\/10.1200\/jco.2001.19.3.697","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}